Massachusetts-based biotech TheracosBio announced this week that the FDA has approved its diabetes drug bexagliflozin as an adjunct therapy to improve glycemic control in adult patients.
To be sold as Brenzavvy, the drug was tested in 23 clinical trials that enrolled more than 5,000 adults with type 2 diabetes mellitus. The chronic disorder affects more than 33 million Americans, and is normally treated with exercise, healthy diet, and medication to control glucose levels.
Brenzavvy belongs to a class of drugs called SGLT2 inhibitors, also known as “flozins,” that work by preventing sugar reabsorption into the kidneys. In trials, the drug significantly reduced average and fasting blood sugar levels after 24 weeks when used by itself or in combination with other standard-of-care treatments, such as metfmorfin. Brenzavvy is available as 20 mg oral tablets to be taken once daily.
